Floatz logo

Mosunetuzumab

Follicular Lymphoma

Institute of Hematology & Blood Diseases Hospital, Chinamonoclonal_antibodyPhase 3Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
65/ 100

Competitive context

209 Active assets in the Follicular Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2/3BBB
Romidepsin
City of Hope Medical Center
Phase 2BBB
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB
Recombinant Human Hyaluronidase
National Cancer Institute (NCI)
Phase 3BBB

View all 50 →

Same molecule, other indications

Mosunetuzumab is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
high grade B-cell lymphomaDormant
BB
Indicative ·
65 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →